文献速递白血病

抑制Pol I转录通过靶向白血病起始细胞群体治疗小鼠和人类急性髓系白血病

Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population.
PubMed 文献 · Blood · 2017-03-10

本研究揭示RNA聚合酶I(Pol I)转录选择性抑制剂CX-5461能有效治疗侵袭性急性髓系白血病(AML),包括混合谱系白血病驱动的AML,且优于标准化疗。除诱导p53依赖性凋亡外,CX-5461在p53缺失AML体内也显示强效,其生存优势与检查点激酶1/2激活、异常G2/M细胞周期进展及髓系分化诱导相关。急性抑制Pol I转录可减少白血病粒细胞-巨噬细胞祖细胞和白血病起始细胞(LIC)群体并抑制其克隆形成能力。

要点

  • CX-5461有效治疗侵袭性AML且优于标准化疗。
  • CX-5461在p53缺失AML体内亦显示强效。
  • CX-5461减少LIC和粒细胞-巨噬细胞祖细胞群体。

核心结论

  • CX-5461通过靶向LIC群体治疗高度侵袭性AML,显示治疗效用。

研究设计与样本

  • 研究使用小鼠和人类AML模型,包括混合谱系白血病驱动的AML和p53缺失AML。

主要发现

  • CX-5461在p53野生型和p53缺失白血病小鼠中均显示显著生存优势。
  • CX-5461治疗与检查点激酶1/2激活、异常G2/M细胞周期进展及白血病原始细胞髓系分化诱导相关。
  • 急性抑制Pol I转录减少白血病粒细胞-巨噬细胞祖细胞和LIC群体,并抑制其克隆形成能力。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite the development of novel drugs, the prospects for many patients with acute myeloid leukemia (AML) remain dismal. This study reveals that the selective inhibitor of RNA polymerase I (Pol I) transcription, CX-5461, effectively treats aggressive AML, including mixed-lineage leukemia-driven AML, and outperforms standard chemotherapies. In addition to the previously characterized mechanism of action of CX-5461 (ie, the induction of p53-dependent apoptotic cell death), the inhibition of Pol I transcription also demonstrates potent efficacy in p53null AML in vivo. This significant survival advantage in both p53WT and p53null leukemic mice treated with CX-5461 is associated with activation of the checkpoint kinases 1/2, an aberrant G2/M cell-cycle progression and induction of myeloid differentiation of the leukemic blasts. The ability to target the leukemic-initiating cell population is thought to be essential for lasting therapeutic benefit. Most strikingly, the acute inhibition of Pol I transcription reduces both the leukemic granulocyte-macrophage progenitor and leukemia-initiating cell (LIC) populations, and suppresses their clonogenic capacity. This suggests that dysregulated Pol I transcription is essential for the maintenance of their leukemia-initiating potential. Together, these findings demonstrate the therapeutic utility of this new class of inhibitors to treat highly aggressive AML by targeting LICs.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Hein N, Cameron DP, Hannan KM, et al. Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population. Blood. 2017. PMID: 28283481. doi:10.1182/blood-2016-05-718171

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。